Adalimumab biosimilar - Coherus BioSciences

Drug Profile

Adalimumab biosimilar - Coherus BioSciences

Alternative Names: CHS-1420

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator Coherus Biosciences
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Plaque psoriasis

Most Recent Events

  • 10 Jan 2017 Top-line efficacy data from a phase III trial in Psoriasis released by Coherus Biosciences
  • 09 Nov 2016 Coherus BioSciences has patent protection for adalimumab biosimilar in USA
  • 09 Nov 2016 Coherus BioSciences plans a pharmacokinetic trial for Plaque psoriasis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top